Press release
Castrate-Resistant Prostate Cancer Market to Exceed USD 30.1 Billion by 2034
Castrate-Resistant Prostate Cancer
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71187
With the growing global prostate cancer burden, expanding geriatric population, and strong research focus on novel therapeutics, the CRPC market is gaining substantial momentum. Today, therapies range from androgen receptor inhibitors and chemotherapy to next-generation targeted therapies and radiopharmaceuticals. As precision oncology advances, the outlook for CRPC patients continues to improve, driving strong growth prospects for the market through 2034.
Market Overview
• Market Size 2024: USD 14.5 billion
• Market Forecast 2034: USD 30.1 billion
• CAGR (2025-2034): 7.5%
Key Highlights
• Growth Drivers:
o Rising incidence of prostate cancer globally, particularly in aging male populations
o Advancements in androgen receptor-targeted therapies (enzalutamide, apalutamide, darolutamide)
o Expanding use of immunotherapy and radiopharmaceuticals in advanced cancer care
o Increasing adoption of precision medicine and biomarker-driven treatments
o Favorable regulatory approvals and accelerated drug pipelines
• Challenges:
o High treatment costs and reimbursement hurdles in developing economies
o Adverse side effects associated with chemotherapy and hormonal therapies
o Resistance development to androgen receptor inhibitors over time
o Disparities in access to advanced therapies across regions
• Leading Players:
Key companies shaping the market include Johnson & Johnson (Janssen Biotech), Pfizer, Astellas Pharma, Bayer AG, Novartis, Bristol-Myers Squibb, Sanofi, and AstraZeneca. Many are investing heavily in immuno-oncology, radioligand therapies, and next-generation androgen receptor inhibitors.
Segmentation Analysis
By Therapy Type
• Hormonal therapies (androgen receptor inhibitors, CYP17 inhibitors)
• Chemotherapy (docetaxel, cabazitaxel)
• Immunotherapy (checkpoint inhibitors, cancer vaccines)
• Radiopharmaceuticals (radium-223, lutetium-based therapies)
• Targeted therapies (PARP inhibitors, precision oncology drugs)
By Mechanism of Action
• Androgen receptor (AR) inhibitors
• CYP17 enzyme inhibitors
• Radioligand therapies
• PARP inhibitors
• Others (emerging small molecules, bispecific antibodies)
By Route of Administration
• Oral
• Injectable
By End User
• Hospitals & oncology centers
• Specialty clinics
• Research institutes
• Homecare settings
By Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
Segmentation Summary:
The hormonal therapy segment dominates the market, especially androgen receptor inhibitors, due to their efficacy and widespread clinical use. However, radiopharmaceuticals and PARP inhibitors are expected to grow fastest, thanks to increasing adoption of precision oncology and biomarker-guided therapies. Hospitals remain the key end users, while homecare adoption is rising with the availability of oral medications.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71187/castrate-resistant-prostate-cancer-crpc-market
Regional Analysis
North America
• Holds the largest market share, led by the U.S., due to high prostate cancer prevalence, advanced healthcare infrastructure, and strong R&D activity.
• Rapid FDA approvals and widespread access to novel therapies strengthen growth.
Europe
• Second-largest market, supported by government healthcare programs, robust oncology research, and reimbursement policies.
• Germany, France, and the UK dominate CRPC drug adoption.
Asia-Pacific
• Expected to post the fastest CAGR (2025-2034).
• Rising cancer incidence, expanding healthcare spending, and increasing clinical trial activity in China, India, and Japan are major growth drivers.
Middle East & Africa
• Moderate growth due to increasing oncology investments in GCC countries and South Africa.
• Barriers remain in rural and low-income regions.
Latin America
• Brazil and Mexico lead adoption, with growing demand for affordable chemotherapy and targeted therapies.
Regional Summary:
North America and Europe lead today's market, but Asia-Pacific is projected to emerge as the fastest-growing region over the next decade, reflecting demographic changes, higher awareness, and expanding healthcare access.
Market Dynamics
Key Growth Drivers
• Expanding aging male population, driving higher prostate cancer prevalence
• Advances in androgen receptor inhibitors, radioligand therapy, and PARP inhibitors
• Increasing use of companion diagnostics and biomarkers for treatment selection
• Rising clinical trials and drug approvals in oncology
• Shift toward personalized medicine and outpatient oral therapies
Key Challenges
• High treatment costs and unequal access across regions
• Resistance to current drugs, requiring frequent therapy switches
• Adverse side effects reducing patient compliance
• Regulatory hurdles delaying commercialization in emerging markets
Latest Trends
• Expansion of radiopharmaceuticals (e.g., lutetium-177 based therapies)
• Integration of AI and genomic profiling in therapy planning
• Combination regimens (hormonal + immunotherapy, radiopharmaceutical + targeted therapy)
• Focus on oral drug formulations to reduce hospital visits
• Partnerships between pharma and biotech firms to accelerate innovation
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71187
Competitor Analysis
Major Players
• Johnson & Johnson (Janssen Biotech)
• Pfizer Inc.
• Astellas Pharma Inc.
• Bayer AG
• Novartis AG
• AstraZeneca
• Sanofi S.A.
• Bristol-Myers Squibb
• Clovis Oncology (PARP inhibitors segment)
• Blue Earth Diagnostics (radiopharmaceuticals)
Competitive Summary
The CRPC market is highly competitive and innovation-driven. Johnson & Johnson, Pfizer, and Astellas dominate hormonal therapy with leading AR inhibitors such as enzalutamide and apalutamide. Bayer and Novartis are strong in radiopharmaceuticals, while AstraZeneca and Clovis Oncology are leaders in PARP inhibitors.
Intense competition centers around pipeline innovations, patent expirations, pricing strategies, and global expansions. Many players are also pursuing collaborations with diagnostic firms to integrate biomarker-based patient selection into treatment protocols.
Conclusion
The Castrate-Resistant Prostate Cancer (CRPC) market is undergoing rapid transformation, shaped by innovative drug pipelines, targeted therapies, and precision oncology approaches. With prostate cancer incidence expected to rise in aging populations, CRPC treatment demand will continue to grow steadily over the next decade.
By 2034, the market will reach USD 30.1 billion, expanding at a CAGR of 7.5%, making it one of the most dynamic therapeutic segments in oncology.
Key Takeaways
• Market Size: USD 14.5 billion (2024) → USD 30.1 billion (2034)
• CAGR: 7.5% (2025-2034)
• Top Region: North America (largest), Asia-Pacific (fastest growth)
• Leading Therapies: Androgen receptor inhibitors, radiopharmaceuticals, PARP inhibitors
• Major Players: J&J, Pfizer, Astellas, Bayer, Novartis, AstraZeneca, Sanofi, BMS
• Outlook: Strong opportunities in targeted oncology, personalized therapies, and biomarker-driven drug development will define the CRPC market through 2034.
This report is also available in the following languages : Japanese (去勢抵抗性前立腺がん(CRPC)市場), Korean (거세 저항성 전립선암(CRPC) 시장), Chinese (去势抵抗性前列腺癌(CRPC)市场), French (Marché du cancer de la prostate résistant à la castration (CRPC)), German (Markt für kastrationsresistenten Prostatakrebs (CRPC)), and Italian (Mercato del cancro alla prostata resistente alla castrazione (CRPC)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71187/castrate-resistant-prostate-cancer-crpc-market#request-a-sample
Our More Reports:
Asphyxia Market
https://exactitudeconsultancy.com/reports/71485/asphyxia-market
Bronchial Spasms Market
https://exactitudeconsultancy.com/reports/71487/bronchial-spasms-market
Chronic Bronchitis Market
https://exactitudeconsultancy.com/reports/71489/chronic-bronchitis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Castrate-Resistant Prostate Cancer Market to Exceed USD 30.1 Billion by 2034 here
News-ID: 4162232 • Views: …
More Releases from Exactitude Consultancy
Psoriasis Market Emerging Trends and Growth Prospects 2034
Introduction
Psoriasis is a chronic, immune-mediated skin disease affecting more than 125 million people worldwide. Characterized by red, scaly plaques, the condition significantly impacts quality of life and is often associated with comorbidities such as psoriatic arthritis, cardiovascular disease, and depression.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71327
Management has historically relied on topical agents and systemic therapies, but the introduction of biologics and targeted oral small molecules has revolutionized…
Myasthenia Gravis Market to Reach USD 2.5 Billion by 2034
Myasthenia gravis (MG) is a rare, chronic autoimmune neuromuscular disorder characterized by muscle weakness, fatigue, and impaired communication between nerves and muscles. It is primarily caused by antibodies targeting acetylcholine receptors (AChR), muscle-specific kinase (MuSK), or related proteins. Without treatment, MG can cause severe disability and life-threatening respiratory complications.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71325
Historically, therapy centered on cholinesterase inhibitors, corticosteroids, and immunosuppressants, but the treatment landscape…
Leukocyte Adhesion Deficiency Market Projected to Reach USD 1.2 Billion by 2034
Leukocyte adhesion deficiency (LAD) is a rare primary immunodeficiency disorder caused by genetic defects that impair the ability of white blood cells (leukocytes) to migrate to infection sites. This results in severe recurrent infections, impaired wound healing, and high mortality in early life if untreated.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71323
Traditionally managed with antibiotics, antifungals, and hematopoietic stem cell transplantation (HSCT), the treatment paradigm is now shifting…
Systemic Lupus Erythematosus (SLE) Market Detailed Industry Report Analysis 2025 …
Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease where the immune system attacks multiple organ systems, including skin, joints, kidneys, and blood vessels. It is often unpredictable, with flare-ups and remissions that complicate management. Symptoms range from fatigue and skin rashes to life-threatening organ damage.
While conventional treatments such as corticosteroids, antimalarials, and immunosuppressants remain central, recent years have seen significant advances with biologics, targeted therapies, and precision medicine approaches.…
More Releases for CRPC
Castration-Resistant Prostate Cancer (CRPC) Market Analysis, Emerging Therapies, …
Castration-resistant prostate cancer (CRPC) represents one of the most challenging stages in prostate cancer progression. Despite androgen-deprivation therapy (ADT) being the gold standard for initial treatment, many patients eventually develop resistance, leading to CRPC - a condition associated with high morbidity and limited survival outcomes.
With an aging global population, increasing screening rates, and rising incidence of prostate cancer, the demand for advanced CRPC treatment solutions is growing rapidly. Over the…
(2022-2028) Castration-Resistant Prostate Cancer (CRPC) /HRPCA Therapeutics Mark …
The Castration-Resistant Prostate Cancer (CRPC) /HRPCA Therapeutics report compiles the market information depending upon market development and growth factors, optimizing the growth path. In addition, it highlights the strategies and market share of the leading vendors in the particular market. The report follows a robust research methodology model that helps to make informed decisions. It obtains both qualitative and quantitative market information supported by primary research.
The Castration-Resistant Prostate Cancer (CRPC)…
Understanding COVID-19’s impact on the Castration-Resistant Prostate Cancer (C …
Global CRPC therapeutics market would generate a revenue of $9.5 billion by 2020, registering a CAGR of 9.1% from 2015 to 2020. Hormonal therapy segment spearheads among all the therapy types, governing around 4/5th of the global market value in 2014 and would sustain its market position throughout 2020.
Download free sample Report @ alliedmarketresearch.com/request-sample/694
The global CPRC therapeutics market has witnessed high growth in the past few years and would continue…
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Siz …
Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough…
Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Res …
This report studies Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering
Astellas
Johnson & Johnson
Sanofi
Dendreon
Bayer
To Get Sample Copy of Report visit @ http://www.qyresearchreports.com/sample/sample.php?rep_id=905816&type=E
Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth…
Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market to Reach $9.5 Bi …
The principal and key strategy adopted by the leading players in the market is product launch. In order to implement the strategy, acquisitions and partnerships/collaborations have been the key strategies adopted by the leading industry players. The key companies profiled in the report are Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation, Bayer AG, and others.
CRPC Therapeutics Market Report, published by Allied Market Research, forecasts that the global market…
